会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明专利
    • Substituted benzimidazole as kinase inhibitor
    • 取代苄嘧菌胺作为激酶抑制剂
    • JP2013060458A
    • 2013-04-04
    • JP2012264553
    • 2012-12-03
    • Novartis Agノバルティス アーゲー
    • AIKAWA MINA EAMIRI PAYMANDOVE JEFFREY HLEVINE BARRY HASKELLMCBRIDE CHRISTOPHERPICK TERESA EPOON DANIEL JRAMURTHY SAVITHRIRENHOWE PAUL ASHAFER CYNTHIASTUART DARRINSUBRAMANIAN SHARADHA
    • C07D401/14A61K31/4439A61K31/496A61P35/00A61P35/02A61P43/00C07D405/14
    • C07D401/14Y02P20/55
    • PROBLEM TO BE SOLVED: To provide: new substituted benzimidazole compounds, their tautomers, stereoisomers, polymorphs, esters, metabolites, and prodrugs; the pharmaceutically acceptable salts of the compounds, tautomers, stereoisomers, polymorphs, esters, metabolites, and prodrugs; compositions of any of the embodiments together with pharmaceutically acceptable carriers; and uses of any of the embodiments, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cancer.SOLUTION: The new substituted benzimidazole compounds of formula (I), compositions, and methods of inhibition of kinase activity associated with carcinogenicity in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    • 待解决的问题:提供:新取代的苯并咪唑化合物,其互变异构体,立体异构体,多晶型物,酯,代谢物和前药; 化合物,互变异构体,立体异构体,多晶型物,酯,代谢物和前药的药学上可接受的盐; 任何实施方案的组合物和药学上可接受的载体; 以及任何实施方案的单独使用或与至少一种其它治疗剂组合用于预防或治疗癌症中的用途。 提供了式(I)的新取代的苯并咪唑化合物,组合物和抑制与人或动物受试者中致癌性相关的激酶活性的方法。 在某些实施方案中,化合物和组合物有效地抑制至少一种丝氨酸/苏氨酸激酶或受体酪氨酸激酶的活性。 化合物和组合物可以单独使用或与用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的病症例如癌症的至少一种另外的药物组合使用。 版权所有(C)2013,JPO&INPIT